Thornburg Investment Management Inc. cut its position in shares of Shire PLC (NASDAQ:SHPG) by 4.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 105,845 shares of the biopharmaceutical company’s stock after selling 4,922 shares during the period. Thornburg Investment Management Inc.’s holdings in Shire were worth $16,209,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC boosted its position in Shire by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares during the period. Pacer Advisors Inc. purchased a new stake in shares of Shire in the 2nd quarter valued at $171,000. Stephens Inc. AR raised its position in Shire by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 228 shares during the period. Ingalls & Snyder LLC boosted its stake in shares of Shire by 10.8% in the second quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 125 shares during the period. Finally, Aureus Asset Management LLC purchased a new position in Shire in the 2nd quarter valued at $212,000. 62.41% of the stock is owned by hedge funds and other institutional investors.

Shares of Shire PLC (SHPG) traded down $0.79 during mid-day trading on Friday, hitting $148.75. 629,100 shares of the stock traded hands, compared to its average volume of 1,143,943. The company has a market cap of $44,916.84, a P/E ratio of 10.28, a price-to-earnings-growth ratio of 0.83 and a beta of 1.60. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a 12-month low of $137.17 and a 12-month high of $192.15.

Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the consensus estimate of $3.64 by $0.17. Shire had a net margin of 15.00% and a return on equity of 6.92%. The business had revenue of $3.70 billion during the quarter. During the same quarter in the prior year, the firm posted $3.17 EPS. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. equities analysts expect that Shire PLC will post 15 earnings per share for the current year.

Several equities research analysts recently commented on the stock. Jefferies Group reiterated a “hold” rating and issued a $206.00 price objective (down from $216.00) on shares of Shire in a research report on Wednesday, August 9th. Barclays cut Shire from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Royal Bank Of Canada restated a “buy” rating and issued a $213.00 price target on shares of Shire in a report on Monday, October 2nd. BidaskClub lowered Shire from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Cantor Fitzgerald set a $222.00 price target on Shire and gave the company a “buy” rating in a report on Tuesday, August 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $212.18.

TRADEMARK VIOLATION WARNING: “Shire PLC (SHPG) Position Lowered by Thornburg Investment Management Inc.” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.